MONTREAL and WALTHAM, Mass.--(BUSINESS WIRE)--Abbott Canada, the Canadian affiliate of Abbott, has launched Oscient Pharmaceuticals Corporation’s (Nasdaq: OSCI) fluoroquinolone antibiotic, FACTIVE® (gemifloxacin mesylate) tablets in Canada for the five-day treatment of acute bacterial exacerbations of chronic bronchitis (AECB). Oscient granted the commercialization rights for FACTIVE to Abbott Canada in August of last year.
